360 related articles for article (PubMed ID: 30160789)
21. The simpler, the better: oral arsenic for acute promyelocytic leukemia.
Zhu HH; Hu J; Lo-Coco F; Jin J
Blood; 2019 Aug; 134(7):597-605. PubMed ID: 31113776
[TBL] [Abstract][Full Text] [Related]
22. Oral Realgar-Indigo Naturalis Formula Plus Retinoic Acid for Acute Promyelocytic Leukemia.
Lou Y; Ma Y; Jin J; Zhu H
Front Oncol; 2020; 10():597601. PubMed ID: 33614484
[TBL] [Abstract][Full Text] [Related]
23. Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group.
Adès L; Thomas X; Bresler AG; Raffoux E; Spertini O; Vey N; Marchand T; Récher C; Pigneux A; Girault S; Deconinck E; Gardin C; Tournilhac O; Lambert JF; Chevallier P; de Botton S; Lejeune J; Dombret H; Chevret S; Fenaux P
Haematologica; 2018 Dec; 103(12):2033-2039. PubMed ID: 30026341
[TBL] [Abstract][Full Text] [Related]
24. Research on different compound combinations of Realgar-Indigo naturalis formula to reverse acute promyelocytic leukemia arsenic resistance by regulating autophagy through mTOR pathway.
Li R; Xue C; Pan Y; Li G; Huang Z; Xu J; Zhang J; Chen X; Hou L
J Ethnopharmacol; 2024 May; 326():117778. PubMed ID: 38310990
[TBL] [Abstract][Full Text] [Related]
25. [Comparison of Curative Effect between Fu Fang Huang Dai Pian and Arsenic Trioxide in Treatment of 45 Patients with Acute Promyelocytic Leukaemia].
Wang J; Huang JB; Liu ZL; Zhang BH; Xu HG; Xue HM; Chen C
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1605-1610. PubMed ID: 29262883
[TBL] [Abstract][Full Text] [Related]
26. Bayesian network meta-analysis comparing five contemporary treatment strategies for newly diagnosed acute promyelocytic leukaemia.
Wu F; Wu D; Ren Y; Duan C; Chen S; Xu A
Oncotarget; 2016 Jul; 7(30):47319-47331. PubMed ID: 27322078
[TBL] [Abstract][Full Text] [Related]
27. Improved Outcomes of All-trans-retinoic Acid and Arsenic Trioxide Plus Idarubicin as a Frontline Treatment in Adult Patients With Acute Promyelocytic Leukemia.
Yang S; Ma R; Yuan X; Jiang L; Shi J; Yang J; Lei P; Zang Y; Chen X; Zhang Y; Liu Z; Guo J; Zhang L; Zhu X; Zhu Z
Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e382-e391. PubMed ID: 32336675
[TBL] [Abstract][Full Text] [Related]
28. Outcome for pediatric acute promyelocytic leukemia patients at Children's Oncology Group sites on the Leukemia Intergroup Study CALGB 9710 (Alliance).
Kutny MA; Geyer S; Laumann KM; Gregory J; Willman CL; Stock W; Larson RA; Powell BL; Feusner JH
Pediatr Blood Cancer; 2019 Mar; 66(3):e27542. PubMed ID: 30393935
[TBL] [Abstract][Full Text] [Related]
29. Arsenic Combined With All-Trans Retinoic Acid for Pediatric Acute Promyelocytic Leukemia: Report From the CCLG-APL2016 Protocol Study.
Zheng H; Jiang H; Hu S; Liao N; Shen D; Tian X; Hao G; Jin R; Li J; Fang Y; Ju X; Liu A; Wang N; Zhai X; Zhu J; Hu Q; Li L; Liu W; Sun L; Wang L; Dai Y; Feng X; Li F; Liang H; Luo X; Yan M; Yin Q; Chen Y; Han Y; Qu L; Tao Y; Gao H; He Z; Lin L; Luo J; Pan K; Zhang J; Zhang R; Zhou M; Zhang Y; Wang L; Zhang R; Xiao P; Ling Y; Peng X; Peng Y; Wang T;
J Clin Oncol; 2021 Oct; 39(28):3161-3170. PubMed ID: 34077242
[TBL] [Abstract][Full Text] [Related]
30. Comparison of induction therapy in non-high risk acute promyelocytic leukemia with arsenic trioxide or in combination with ATRA.
Ghavamzadeh A; Jalili M; Rostami S; Yaghmaie M; Aliabadi LS; Mousavi SA; Vaezi M; Fumani HK; Jahani M; Alimoghaddam K
Leuk Res; 2018 Mar; 66():85-88. PubMed ID: 29407588
[TBL] [Abstract][Full Text] [Related]
31. [All-trans retinoic acid/arsenic trioxide combination therapy for a patient with acute promyelocytic leukemia on dialysis].
Nagao R; Hosoba R; Yahagi Y; Gunji T; Uryu H; Hattori D; Momoki M; Yamazaki H
Rinsho Ketsueki; 2019; 60(10):1431-1435. PubMed ID: 31695003
[TBL] [Abstract][Full Text] [Related]
32. Dissection of scientific compatibility of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia from the perspective of toxicology.
Jiang Z; Sun Y; Wu Z; Tang M; Ye A; Tu B; Yi J; Xu H; Gao Y
J Ethnopharmacol; 2023 Dec; 317():116895. PubMed ID: 37467822
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of Compound Huangdai Tablets combined with all-trans retinoic acid for treatment of acute promyelocytic leukemia: Clinical evidence and potential mechanisms.
Huang Q; Wang T; Xiong Y; Qu L; Yin Q; Zou W
Chin Herb Med; 2022 Jan; 14(1):154-165. PubMed ID: 36120125
[TBL] [Abstract][Full Text] [Related]
34. Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction for Pediatric Patients With Acute Promyelocytic Leukemia: Report From the Children's Oncology Group Phase III Historically Controlled Trial AAML0631.
Kutny MA; Alonzo TA; Gerbing RB; Wang YC; Raimondi SC; Hirsch BA; Fu CH; Meshinchi S; Gamis AS; Feusner JH; Gregory JJ
J Clin Oncol; 2017 Sep; 35(26):3021-3029. PubMed ID: 28767288
[TBL] [Abstract][Full Text] [Related]
35. [Arsenic trioxide in combination with all-trans retinoic acid for acute promyelocytic leukemia: a systematic review and meta-analysis].
Xu SN; Chen JP; Liu JP; Xia Y
Zhong Xi Yi Jie He Xue Bao; 2009 Nov; 7(11):1024-34. PubMed ID: 19912733
[TBL] [Abstract][Full Text] [Related]
36. An effective and chemotherapy-free strategy of all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia in all risk groups (APL15 trial).
Wang HY; Gong S; Li GH; Yao YZ; Zheng YS; Lu XH; Wei SH; Qin WW; Liu HB; Wang MC; Xi JY; Chen LM; Zhang M; Zhang XX; Zhang HY; Zhang CS; Wald DN; Zhu HH; Liu L; He PC
Blood Cancer J; 2022 Nov; 12(11):158. PubMed ID: 36404343
[TBL] [Abstract][Full Text] [Related]
37. Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial.
Platzbecker U; Avvisati G; Cicconi L; Thiede C; Paoloni F; Vignetti M; Ferrara F; Divona M; Albano F; Efficace F; Fazi P; Sborgia M; Di Bona E; Breccia M; Borlenghi E; Cairoli R; Rambaldi A; Melillo L; La Nasa G; Fiedler W; Brossart P; Hertenstein B; Salih HR; Wattad M; Lübbert M; Brandts CH; Hänel M; Röllig C; Schmitz N; Link H; Frairia C; Pogliani EM; Fozza C; D'Arco AM; Di Renzo N; Cortelezzi A; Fabbiano F; Döhner K; Ganser A; Döhner H; Amadori S; Mandelli F; Ehninger G; Schlenk RF; Lo-Coco F
J Clin Oncol; 2017 Feb; 35(6):605-612. PubMed ID: 27400939
[TBL] [Abstract][Full Text] [Related]
38. [Acute promyelocytic leukemia: state-of-the-art management].
Asou N
Rinsho Ketsueki; 2018; 59(6):725-734. PubMed ID: 29973452
[TBL] [Abstract][Full Text] [Related]
39. The economic research of arsenic trioxide for the treatment of newly diagnosed acute promyelocytic leukemia in China.
Chen X; Hong Y; Zheng P; You X; Feng J; Huang Z; Wang Y
Cancer; 2020 Jan; 126(2):311-321. PubMed ID: 31714584
[TBL] [Abstract][Full Text] [Related]
40. Outcomes of high-risk acute promyelocytic leukemia patients treated with arsenic trioxide (ATO)/all trans retinoic acid (ATRA) based induction and consolidation without maintenance phase: A case Series.
Shah G; Mikhail FM; Bachiasvili K; Vachhani P; Erba HP; Papadantonakis N
Hematol Oncol Stem Cell Ther; 2020 Sep; 13(3):143-146. PubMed ID: 31629725
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
